Navigation Links
Jefferson researcher awarded NIH grant
Date:12/4/2008

PHILADELPHIA Scott Mintzer, M.D., assistant professor in the Department of Neurology at Jefferson Medical College of Thomas Jefferson University, and director of the Epilepsy Monitoring Unit at the Jefferson Comprehensive Epilepsy Center of Jefferson Hospital for Neuroscience was recently awarded a Junior Investigator grant from the National Institutes of Health (NIH) to study the adverse metabolic effects of antiepileptic seizure medications. The K23 grant, also known as the Mentored Patient-oriented Research Career Development Award, totals $843,000 and will be dispersed over a five-year period.

The K23 award is to support the career development of investigators who have made a commitment to focus their endeavors on patient-oriented research. This mechanism provides support for three to five years of supervised study and research for clinically trained professionals who have the potential to develop into productive, clinical investigators focusing on patient-oriented research.

"I am honored to have been chosen to receive such a prestigious grant," said Dr. Mintzer. "It's my hope that this research into the possible cardiovascular side effects of anti-seizure medications may help doctors manage the care of patients with seizures more effectively while not adversely affecting other aspects of their overall health."

The grant involves two randomized patient studies designed to ascertain the metabolic effects of common anti-seizure medications on risk factors for heart attack and stroke including cholesterol and C-reactive protein levels. The first study includes 90 patients with epilepsy, who will be followed over several months, to look at whether changes in seizure medication can improve cholesterol and other blood chemical levels on a short-term and long-term basis.

The second study follows 200 patients who have had a subarachnoid hemorrhage, or bleeding in the lining that surrounds the brain. Traditionally this patient population is prescribed anti-seizure medications for a certain period of time following treatment. Trial participants will be randomly broken into four groups and prescribed either Dilantin, Keppra, Depakote or no medication to see if there are any potential short- or long-term effects on cardiovascular risk factors.


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
2. Jefferson immunology researchers halt lethal rabies infection in brain
3. Jefferson radiation oncologists use real-time system to plant seeds against cancer
4. Jefferson researchers find personalized interventions key to improving colon cancer screening rates
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
7. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology: